Chugai Pharmaceutical Co (MEX:4519N) Short-Term Debt: MXN0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:4519N Chugai Pharmaceutical Co Ltd MEX:4519N
97 GF Score
Price MXN825.61
GF Value MXN939.06
! 1 Warning Sign
View Full Analysis

What is Chugai Pharmaceutical Co Short-Term Debt?

Chugai Pharmaceutical Co MEX:4519N 97 Short-Term Debt is MXN0 Mil as of Jun. 2026. GuruFocus rates MEX:4519N with a GF Score™ of 97/100 and a GF Value™ of MXN939.06. The stock has 1 warning sign investors should review.

Chugai Pharmaceutical Co's Short-Term Debt for the quarter that ended in Jun. 2026 was MXN0 Mil.

Chugai Pharmaceutical Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Chugai Pharmaceutical Co Short-Term Debt Related Terms

Chugai Pharmaceutical Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Chugai Pharmaceutical Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chugai Pharmaceutical Co Short-Term Debt Chart

Chugai Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Chugai Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:4519N
97GF Score
Chugai Pharmaceutical Co Ltd MEX:4519N
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of MXN0 Mil mean?
Chugai Pharmaceutical Co (MEX:4519N) has a Short-Term Debt of MXN0 Mil as of Jun. 2026.
Is Chugai Pharmaceutical Co's Short-Term Debt too high?
Chugai Pharmaceutical Co's current Short-Term Debt is MXN0 Mil. Overall, Chugai Pharmaceutical Co has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Short-Term Debt compare to LLY and JNJ?
Chugai Pharmaceutical Co's Short-Term Debt of MXN0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Chugai Pharmaceutical Co's current Short-Term Debt is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Chugai Pharmaceutical Co (MEX:4519N) has a current Short-Term Debt of MXN0 Mil. The stock's GF Value™ is MXN939.06, compared to a current price of MXN825.61 — trading 12.1% below its estimated fair value. The current Short-Term Debt is MXN0 Mil. Chugai Pharmaceutical Co's overall GF Score™ is 97/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Chugai Pharmaceutical Co (MEX:4519N), the current Short-Term Debt is MXN0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chugai Pharmaceutical Co (MEX:4519N) Overvalued in 2026?

Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued. The current stock price of MXN825.61 is trading 12.1% below its estimated GF Value™ of MXN939.06.

Key valuation signals for MEX:4519N:

  • Short-Term Debt: MXN0 Mil
  • GF Value™: MXN939.06 vs. price of MXN825.61 (12.1% below fair value)
  • GF Score™: 97/100 with 1 warning sign

No single metric tells the full story. See the MEX:4519N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chugai Pharmaceutical Co Business Description

Address 2-1-1 Muromachi, Nihonbashi, 12th Floor, Nihonbashi Mitsui Tower, Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
97GF Score

Get the complete analysis for MEX:4519N

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN825.61
Price
MXN939.06
GF Value